News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 1, 2024

The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

Author(s)Ryan Haumschild, PharmD, MS, MBA, Wanda Filer, MD, MBA, Marty J. Feltner, PharmD

Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.

Episodes in this series

A panel of 5 experts on RSV

EP. 1 Overview of RSV Patient Populations

Marty J. Feltner, PharmD, an expert on RSV

EP. 2 Complications Associated with RSV Infections

A panel of 5 experts on RSV

EP. 3 The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

A panel of 5 experts on RSV

EP. 4 RSV: Risk Factors and How It’s Spread

A panel of 5 experts on RSV

EP. 5 Diagnostic Practices for RSV

A panel of 5 experts on RSV

EP. 6 Increasing Awareness of RSV Vaccines in At-Risk Patients

A panel of 5 experts on RSV

EP. 7 Shared Decision-Making Practices in RSV

A panel of 5 experts on RSV

EP. 8 Financial and Clinical Benefits of RSV Immunization

A panel of 5 experts on RSV

EP. 9 The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

A panel of 5 experts on RSV

EP. 10 Addressing Vaccine Fatigue

A panel of 5 experts on RSV

EP. 11 Identifying Patients Eligible for RSV Vaccine

A panel of 5 experts on RSV

EP. 12 Current and Potential Obstacles Related to Administering RSV Vaccines

A panel of 5 experts on RSV

EP. 13 Improving Insurance Coverage for RSV Vaccines

A panel of 5 experts on RSV

EP. 14 Improving RSV Vaccination Rates and Addressing Misinformation

A panel of 5 experts on lung cancer

EP. 15 Key Takeaways on RSV Vaccination

Video content above is prompted by the following questions:

Please describe the economic burden of RSV, especially in adults aged 50-59 and those 60 and older.
What are the main drivers of healthcare resource utilization in high-risk patients with RSV?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Baby on nebulizer. | Image credit: zilvergolf - stock.adobe.com

Clesrovimab Demonstrates Safety Through a Second RSV Season in High-Risk Infants

BySabrina McCrear

July 23rd 2026

Child receiving vaccine | Image credit: Drazen - stock.adobe.com

Experts Warn That CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust

ByBrooke McCormick

Published: January 27th 2026 | Updated: February 3rd 2026

CDC headquarters | Image Credit: Katherine Welles - stock.adobe.com

Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns

ByBrooke McCormick

January 26th 2026

Doctor talking with older patient | Image credit: ryanking999 - stock.adobe.com

Meta-Analysis Supports RSV Vaccine Efficacy and Safety in Older Adults

ByKimberly Rath, PharmD

December 30th 2025

Findings suggest that early monitoring of chemokines could help facilitate treatment planning by more quickly identifying patients at risk of severe disease. | Image credit: Rochu_2008 - stock.adobe.com

Potential Biomarkers of RSV Bronchiolitis Severity Identified

ByJared Kaltwasser

December 26th 2025

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care